99 related articles for article (PubMed ID: 28245655)
1. Economic burden of hypoglycemia with basal insulin in type 2 diabetes.
Fonseca V; Chou E; Chung HW; Gerrits C
Am J Manag Care; 2017 Feb; 23(2):114-122. PubMed ID: 28245655
[TBL] [Abstract][Full Text] [Related]
2. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
Dalal MR; Kazemi M; Ye F; Xie L
Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and healthcare resource utilization associated with medically attended hypoglycemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting.
Escalada J; Liao L; Pan C; Wang H; Bala M
Curr Med Res Opin; 2016 Sep; 32(9):1557-65. PubMed ID: 27173946
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization.
Dalal MR; Kazemi MR; Ye F
Curr Med Res Opin; 2017 Feb; 33(2):209-214. PubMed ID: 27737571
[TBL] [Abstract][Full Text] [Related]
5. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
[TBL] [Abstract][Full Text] [Related]
6. A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus.
Bhattacharya R; Zhou S; Wei W; Ajmera M; Sambamoorthi U
J Am Geriatr Soc; 2015 May; 63(5):893-901. PubMed ID: 25955280
[TBL] [Abstract][Full Text] [Related]
7. Frequency and causes of hospitalization in older compared to younger adults with type 2 diabetes in the United States: a retrospective, claims-based analysis.
Fu H; Curtis BH; Xie W; Festa A; Schuster DP; Kendall DM
J Diabetes Complications; 2014; 28(4):477-81. PubMed ID: 24636762
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool.
Hoskins N; Tikkanen CK; Pedersen-Bjergaard U
J Med Econ; 2017 Apr; 20(4):363-370. PubMed ID: 27926814
[TBL] [Abstract][Full Text] [Related]
9. The economic effect of hypoglycemia in a health plan.
Heaton A; Martin S; Brelje T
Manag Care Interface; 2003 Jul; 16(7):23-7. PubMed ID: 12908214
[TBL] [Abstract][Full Text] [Related]
10. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis.
Fu H; Xie W; Curtis B; Schuster D
Curr Med Res Opin; 2014 Sep; 30(9):1787-93. PubMed ID: 24810150
[TBL] [Abstract][Full Text] [Related]
11. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States.
Ganz ML; Wintfeld NS; Li Q; Lee YC; Gatt E; Huang JC
Curr Med Res Opin; 2014 Oct; 30(10):1991-2000. PubMed ID: 24945720
[TBL] [Abstract][Full Text] [Related]
12. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
13. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of hypoglycemia among insulin-treated patients with diabetes.
Sussman M; Sierra JA; Garg S; Bode B; Friedman M; Gill M; Kaufman F; Vigersky R; Menzin J
J Med Econ; 2016 Nov; 19(11):1099-1106. PubMed ID: 27292016
[TBL] [Abstract][Full Text] [Related]
15. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
16. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
[TBL] [Abstract][Full Text] [Related]
17. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
18. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
Asche CV; Luo W; Aagren M
Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
[TBL] [Abstract][Full Text] [Related]
19. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
20. Hypoglycemia-related emergency department visits and hypoglycemia-related hospitalizations among new users of antidiabetes treatments.
Moisan J; Breton MC; Villeneuve J; Grégoire JP
Can J Diabetes; 2013 Jun; 37(3):143-9. PubMed ID: 24070836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
